Ophthalmic Business News

The Residency to Retirement resource center offers insightful and innovative strategies to help physicians reduce taxes, protect assets, invest wisely and build wealth during all phases of their careers.

MELT-300, a combination of midazolam and ketamine administered sublingually before cataract surgery, achieved the primary sedation endpoint in a pivotal phase 2 efficacy and safety study, Melt Pharmaceuticals announced in a press release.

Business was not supposed to be the topic of my last column of 2022.

Iveric Bio has submitted the third and final part of its new drug application for Zimura to the FDA for rolling review, according to a press release.

Caren Mason will retire as president and CEO of STAAR Surgical on Dec. 31, with Thomas “Tom” G. Frinzi tapped as her replacement.

NDS-ECNW has obtained a U.S. patent for its Trimoxi injectable formulation for prophylaxis after cataract surgery, according to a press release.

The FDA approved Iyuzeh for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release from Thea Pharma.

Harrow has entered into an agreement to acquire the exclusive U.S. commercial rights to five FDA-approved ophthalmic products from Novartis, according to a press release.

Through the end of September, the S&P 500 had declined three consecutive quarters and lost nearly 24% of its value.

The FDA granted orphan drug designation to BRM424 for the treatment of neurotrophic keratitis, according to a press release from Brim Biotechnology.